πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12109230

Treatment of neurodegenerative disease with sodium chlorite

The Regents of the University of California Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12109236

Manipulating ARID5B expression in immune cells to promote metabolism, survival, and functi

Regents of the University of Minnesota Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12109258

Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat mal

Inovio Pharmaceuticals, Inc. Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12109239

Methods for production of human hemogenic endothelial cells from pluripotent stem cells an

Astellas Institute for Regenerative Medicine Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12109272

Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and

Corcept Therapeutics Incorporated Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12110491

Selective reduction of allelic variants

Ionis Pharmaceuticals, Inc. Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12109185

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12110520

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12109196

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12110492

RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical comp

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12110502

Models of tauopathy

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12110504

Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected au

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12109260

Zika vaccines and immunogenic compositions, and methods of using the same

Takeda Vaccines, Inc. Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12109228

Treatment of neurodegenerative disease with sodium chlorite

The Regents of the University of California Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12109190

Urolithins as immune response enhancers

Amazentis SA Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12109198

Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

Fulcrum Therapeutics, Inc. Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12108745

Rat model of IgA nephropathy induced with a multimeric recombinant IgA fragment

Northwestern University Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12103960

VEGF traps and mini-traps and methods for treating ocular disorders and cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12104163

Adeno-associated virus vectors for treatment of Rett syndrome

Sarepta Therapeutics, Inc. Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12103958

Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use th

The Regents of the University of California Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12104181

Compositions and methods for treating viral infections targeting TRIM7

The Board of Regents of the University of Texas System Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12104172

Processes for generating TIL products enriched for tumor antigen-specific t-cells

Iovance Biotherapeutics, Inc. Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12104165

Adeno-associated virus with engineered capsid

Tenaya Therapeutics, Inc. Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12104188

Modified caspase-9 polypeptides and methods of use thereof

Allogene Therapeutics, Inc. Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted